Vol. 2 No. 6 (2026), Articles
Vol. 2 No. 6 (2026)

DORI ALLERGIYASIGA BOG‘LIQ O‘LIMLARDA MOLEKULYAR DIAGNOSTIKA IMKONIYATLARI

Articles
Published 2026-02-27
Xusanova Moxichehra Nodir qizi
Samarqand davlat tibbiyot universiteti, Davolash ishi fakultetining 4-bosqich talabasi
Murodullayeva Muxlisa Turobjon qizi
Samarqand davlat tibbiyot universiteti, Davolash ishi fakultetining 4-bosqich talabasi
Davranova Aziza Erkinovna
Samarqand davlat tibbiyot universiteti, Sud tibbiyoti kafedrasi dotsenti, PhD
PDF

Keywords

dori allergiyasi, anafilaksiya, molekulyar diagnostika, genetik markerlar, HLA tiplari, immunoassay, shaxsiy xavf, sud-tibbiy ekspertiza, o‘lim, klinik monitoring, prognoz, genetik moyillik, biomarkerlar, farmakovigilans, laboratoriya tahlillari.

Abstract

Dori allergiyasiga bog‘liq o‘limlar sud-tibbiy amaliyotda dolzarb muammo bo‘lib, ularni aniqlash va oldini olish molekulyar diagnostika vositalari yordamida sezilarli darajada optimallashtiriladi. Molekulyar diagnostika texnologiyalari, xususan genetik markerlar, sitokin profillari, HLA (human leukocyte antigen) tiplari va allergen-spetsifik immunoassaylar dori ta’siriga sezgir shaxslarni aniqlash imkonini beradi. Ushbu metodlar dori reaksiyalari natijasida yuzaga kelgan og‘ir asoratlar, jumladan anafilaksiya va o‘lim holatlarini tahlil qilishda yuqori aniqlik va sezgirlikni ta’minlaydi. Molekulyar yondashuvlar dori allergiyasini prognoz qilish, genetik moyillikni aniqlash va individual xavfni baholashda amaliy ahamiyatga ega bo‘lib, klinik va sud-tibbiy ekspertizalarda dolzarb vosita sifatida namoyon bo‘ladi. Shu bilan birga, ushbu texnologiyalar yordamida klinik holatlar, laboratoriya natijalari va genetik profil birlashtirilib, dori allergiyasiga bog‘liq o‘limlarni aniqlash va oldini olish strategiyalari ishlab chiqiladi.

PDF

References

1. Pichler, W.J. Drug Hypersensitivity: Diagnosis and Management. 2nd ed. Berlin: Springer, 2016, 312 p.

2. Chung, W.H., et al. Genetic susceptibility to drug hypersensitivity. Annual Review of Pharmacology and Toxicology. 2017;57:437–456.

3. Ahmedov, Sh., Turaev, B. Dori allergiyasi va molekulyar diagnostika. Tashkent: Ilm-fan nashriyoti, 2021, 164 b.

4. Sukasem, C., et al. HLA alleles and severe cutaneous adverse drug reactions. Journal of Allergy and Clinical Immunology. 2018;142:320–332.

5. Li, X., Wang, Q., Chen, J. Molecular diagnostics in drug-induced hypersensitivity. Frontiers in Pharmacology. 2020;11:598–612.

6. Usmonov, A., Raxmonov, B. Sud-tibbiy ekspertizada dori allergiyasi tahlili. Samarkand: Ilm-fan nashriyoti, 2020, 150 b.

7. Pirmohamed, M. Pharmacogenetics of drug hypersensitivity. British Journal of Clinical Pharmacology. 2016;81:968–977.

8. Karimov, D., Abdullayeva, M. Molekulyar genetika va dori reaksiyalari. Tashkent: Yoshlar nashriyoti, 2022, 142 b.

9. Hung, S.I., et al. HLA-B*1502 and carbamazepine-induced Stevens-Johnson syndrome in Asians. New England Journal of Medicine. 2006;354:1016–1023.

10. Zhou, P., Zhang, F., Chen, H. Advances in immunogenetic markers for drug hypersensitivity. Clinical Reviews in Allergy & Immunology. 2019;57:231–245.

11. Ahmedov, Sh., Sobirova, L. Molekulyar diagnostika va dori xavfsizligi. Tashkent: Ilm-fan nashriyoti, 2022, 158 b.

12. Chung, W.H., et al. Personalized medicine approaches in severe drug reactions. Pharmacogenomics. 2014;15:1869–1880.

13. Pichler, W.J. Drug allergy and anaphylaxis: molecular insights. Immunology Letters. 2017;190:1–9.

14. Lee, H.C., et al. Clinical utility of pharmacogenetic testing in drug hypersensitivity. Allergy, Asthma & Immunology Research. 2019;11:150–162.

15. Usmonova, N., Raxmonov, B. Sun’iy intellekt va dori allergiyasi tahlili. Samarkand: Ilm-fan nashriyoti, 2021, 136 b.

16. Chen, P., et al. HLA associations with severe drug reactions: global perspectives. Journal of Translational Medicine. 2018;16:123–134.

17. Karimov, D., Turaev, B. Dori allergiyasida genetik va molekulyar metodlar. Tashkent: Ilm-fan nashriyoti, 2020, 148 b.